iTeos Therapeutics Management
Management criteria checks 2/4
iTeos Therapeutics' CEO ist Michel Detheux , ernannt in Aug 2011, hat eine Amtszeit von 12.33 Jahren. Die jährliche Gesamtvergütung beträgt $10.51M , bestehend aus 5.3% Gehalt und 94.7% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.063% der Aktien des Unternehmens, im Wert von $229.69K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.7 Jahre bzw. 3.8 Jahre.
Key information
Michel Detheux
Chief executive officer
US$10.5m
Total compensation
CEO salary percentage | 5.3% |
CEO tenure | 12.7yrs |
CEO ownership | 0.06% |
Management average tenure | 3.8yrs |
Board average tenure | 4.1yrs |
Recent management updates
Recent updates
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Looks Inexpensive But Perhaps Not Attractive Enough
Jan 25iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
Jan 10Industry Analysts Just Upgraded Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Revenue Forecasts By 16%
May 13Investors Give iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares A 25% Hiding
Mar 21The Consensus EPS Estimates For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Just Fell Dramatically
Aug 12iTeos Therapeutics GAAP EPS of $0.16 misses by $1.04
Aug 10iTeos Therapeutics: Too Many Unknowns
Jul 27News Flash: Analysts Just Made A Captivating Upgrade To Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Forecasts
May 11Rainbows and Unicorns: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Became A Lot More Optimistic
Nov 25We Think iTeos Therapeutics (NASDAQ:ITOS) Can Afford To Drive Business Growth
Aug 24iTeos Therapeutics: My Calculations Suggest Q3 Earnings Will Exceed $10 Per Share
Aug 15GlaxoSmithKline - iTeos deal intensifies competition in anti-TIGIT space: Piper Sandler
Jun 15We Think iTeos Therapeutics (NASDAQ:ITOS) Can Easily Afford To Drive Business Growth
Feb 07Is iTeos Therapeutics, Inc. (NASDAQ:ITOS) Popular Amongst Institutions?
Dec 16iTeos Therapeutics EPS misses by $0.11
Nov 12CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | -US$113m |
Sep 30 2023 | n/a | n/a | -US$62m |
Jun 30 2023 | n/a | n/a | -US$28m |
Mar 31 2023 | n/a | n/a | US$12m |
Dec 31 2022 | US$11m | US$556k | US$97m |
Sep 30 2022 | n/a | n/a | US$261m |
Jun 30 2022 | n/a | n/a | US$330m |
Mar 31 2022 | n/a | n/a | US$298m |
Dec 31 2021 | US$6m | US$525k | US$215m |
Sep 30 2021 | n/a | n/a | US$15m |
Jun 30 2021 | n/a | n/a | -US$67m |
Mar 31 2021 | n/a | n/a | -US$50m |
Dec 31 2020 | US$17m | US$463k | -US$43m |
Sep 30 2020 | n/a | n/a | -US$35m |
Jun 30 2020 | n/a | n/a | -US$31m |
Mar 31 2020 | n/a | n/a | -US$28m |
Dec 31 2019 | US$2m | US$460k | -US$27m |
Vergütung im Vergleich zum Markt: MichelDie Gesamtvergütung ($USD10.51M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD2.23M).
Entschädigung vs. Einkommen: MichelDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.
CEO
Michel Detheux (56 yo)
12.7yrs
Tenure
US$10,508,869
Compensation
Dr. Michel Detheux, Ph D, is Chairman of the Board at InnoSkel. He serves as an Independent Chairman at Ona Therapeutics, S.L. since December 2021.He has served as the Chief Executive Officer and Director...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 12.7yrs | US$10.51m | 0.063% $ 302.2k | |
Chief Operating Officer | 4.7yrs | US$2.86m | 0.26% $ 1.3m | |
Chief Financial Officer | 3.8yrs | US$2.08m | 0.054% $ 259.2k | |
Chief Scientific Officer | 2.3yrs | no data | no data | |
VP & Head of Legal | 1.3yrs | no data | no data | |
Vice-President of Human Resources | 4.3yrs | no data | no data | |
Interim Chief Medical Officer | 1.3yrs | no data | no data |
3.8yrs
Average Tenure
50yo
Average Age
Erfahrenes Management: ITOSDas Führungsteam des Unternehmens gilt als erfahren (3.7 Jahre durchschnittliche Betriebszugehörigkeit).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 12.3yrs | US$10.51m | 0.063% $ 302.2k | |
Independent Director | 3.8yrs | US$309.46k | 0% $ 0 | |
Independent Chairman of the Board | 5.8yrs | US$403.46k | 0% $ 0 | |
Independent Director | 4.1yrs | US$245.46k | 0% $ 0 | |
Independent Director | 5.8yrs | US$295.46k | 0% $ 0 | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 3yrs | US$296.96k | 0% $ 0 | |
Independent Director | 3yrs | US$297.96k | 0% $ 0 | |
Chairman of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data |
4.1yrs
Average Tenure
56yo
Average Age
Erfahrener Vorstand: ITOSDie Vorstandsmitglieder gelten als erfahren (3.8 Jahre durchschnittliche Amtszeit).